OLUMIANT: payments to doctors
Payments that named OLUMIANT as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $13M
- Providers
- 16,611
- Transactions
- 111,007
- Average per transaction
- $117
The per-transaction average — $117 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 16,611 providers the average total is $780, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Lilly USA, LLC | $12,322,665 | 95.1% |
| Eli Lilly | $636,143 | 4.9% |
| Eli Lilly Export S.A. Puerto Rico Branch | $4,316 | 0.0% |